Dashboard
Manage Tickers

LLY ELI LILLY & Co

NYSE lilly.com


$ 831.44 $ 16.78 (2.06 %)    

Friday, 24-Oct-2025 13:50:22 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 618.33 $ 2.33 (0.38 %)
DIA $ 472.81 $ 2.90 (0.62 %)
SPY $ 678.29 $ 1.81 (0.27 %)
TLT $ 91.53 $ -0.02 (-0.02 %)
GLD $ 378.53 $ -0.04 (-0.01 %)
$ 821.04
$ 816.01
$ 831.43 x 2
$ 831.70 x 5
$ 813.37 - $ 833.83
$ 622.41 - $ 931.66
2,632,946
na
738.77B
$ 0.59
$ 53.53
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-01-2025 03-31-2025 10-Q
3 02-19-2025 12-31-2024 10-K
4 10-30-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 04-30-2024 03-31-2024 10-Q
7 02-21-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 04-27-2023 03-31-2023 10-Q
11 02-22-2023 12-31-2022 10-K
12 11-01-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 04-29-2022 03-31-2022 10-Q
15 02-23-2022 12-31-2021 10-K
16 10-27-2021 09-30-2021 10-Q
17 08-03-2021 06-30-2021 10-Q
18 04-30-2021 03-31-2021 10-Q
19 02-17-2021 12-31-2020 10-K
20 10-28-2020 09-30-2020 10-Q
21 07-31-2020 06-30-2020 10-Q
22 05-01-2020 03-31-2020 10-Q
23 02-19-2020 12-31-2019 10-K
24 10-25-2019 09-30-2019 10-Q
25 08-02-2019 06-30-2019 10-Q
26 05-02-2019 03-31-2019 10-Q
27 02-19-2019 12-31-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 07-25-2018 06-30-2018 10-Q
30 04-27-2018 03-31-2018 10-Q
31 02-20-2018 12-31-2017 10-K
32 10-27-2017 09-30-2017 10-Q
33 07-28-2017 06-30-2017 10-Q
34 05-01-2017 03-31-2017 10-Q
35 02-21-2017 12-31-2016 10-K
36 10-28-2016 09-30-2016 10-Q
37 07-28-2016 06-30-2016 10-Q
38 04-29-2016 03-31-2016 10-Q
39 02-19-2016 12-31-2015 10-K
40 10-30-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

eli-lillys-new-ebglyss-results-back-flexible-treatment-options-for-atopic-dermatitis
Eli Lilly's New Ebglyss Results Back Flexi...
10/24/2025 16:06:29

Eli Lilly reports new data showing sustained efficacy for Ebglyss with less frequent dosing and strong long-term results for Ol...

eli-lilly-bets-big-on-eye-gene-therapy-that-could-end-repeat-injections
Eli Lilly Bets Big On Eye Gene Therapy Tha...
10/24/2025 15:14:59

Lilly (LLY) to acquire Adverum Biotechnologies (ADVM) for $12.47 per share, with potential CVR payments tied to future milestones.

eli-lilly-options-trading-a-deep-dive-into-market-sentiment
Eli Lilly Options Trading: A Deep Dive int...
10/24/2025 15:00:50

Core News & Articles
Lilly To Acquire Adverum Biotechnologies F...
10/24/2025 12:34:14

mounjaro-maker-eli-lilly-jumps-in-quality-despite-trump-fueled-price-cut-fears
Mounjaro Maker Eli Lilly Jumps In Quality ...
10/24/2025 12:23:00

Eli Lilly jumps to top 10% in quality rankings, showing strong fundamentals even as Trump pushes for weight loss drug price cut...

Core News & Articles
Eli Lilly And Incyte's Baricitinib Deliver...
10/24/2025 10:55:12

This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areat...

eli-lillys-ebglyss-shows-comparable-efficacy-with-q8w-dosing-in-phase-3-adjoin-extension-trial-supporting-less-frequent-dosing-option
Eli Lilly's EBGLYSS Shows Comparable Effic...
10/24/2025 10:50:08

New long-term extension data show approximately 80% of patients achieved or maintained meaningful skin improvement (EASI 75) wi...

eccogene-eyes-hong-kong-ipo-with-experimental-weight-loss-drug-astrazeneca-partnership
Eccogene Eyes Hong Kong IPO With Experimen...
10/23/2025 13:22:01

weight-loss-drugs-are-quietly-exploding-employer-health-insurance-costs-there-is-a-quiet-alarm-bell-going-off
Weight Loss Drugs Are Quietly Exploding Em...
10/23/2025 06:30:19

Employer-sponsored health insurance costs rise for third year, with average family premiums at $27,000 in 2025. Drug costs and ...

heres-how-much-100-invested-in-eli-lilly-20-years-ago-would-be-worth-today
Here's How Much $100 Invested In Eli Lilly...
10/20/2025 15:45:58

no-place-is-risk-free-until-the-world-is-polio-free-bill-gates-urges-global-action-to-close-deadly-immunity-gaps
'No Place Is Risk-Free Until The World Is ...
10/19/2025 07:37:01

Polio cases drop 99.9%, but funding shortfall could undo progress. Last mile hardest as virus exploits immunity gaps.

benzinga-bulls-and-bears-stellantis-papa-johns-oklo--and-trade-tensions-shake-chip-stocks
Benzinga Bulls And Bears: Stellantis, Papa...
10/18/2025 11:41:17

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our t...

trumps-weight-loss-drug-push-may-put-these-etfs-on-a-diet
Trump's Weight-Loss Drug Push May Put Thes...
10/17/2025 20:13:54

Trump's vow to slash weight-loss drug prices sent Hims & Hers tumbling. These ETFs are facing new pressure.

trump-induced-volatility-aside-novo-trades-cheap-while-patents-protect-its-profits-until-2032
Trump-Induced Volatility Aside, Novo Trade...
10/17/2025 18:33:22

Novo Nordisk offers cheap stock with strong moat and long-term growth tailwinds. Trump's drug price cut suggestion caused s...

eli-lilly-shares-are-trading-lower-friday-whats-going-on
Eli Lilly Shares Are Trading Lower Friday:...
10/17/2025 14:44:36

Eli Lilly shares are trading lower Friday, among other GLP-1 drug manufacturers, following Trump's comments that fat-loss ...

novo-vs-lilly-vs-pfizer-who-wins-if-trump-slashes-the-price-of-weight-loss-drugs
Novo Vs. Lilly Vs. Pfizer: Who Wins If Tru...
10/17/2025 14:19:58

Trump's promise to cut cost of Novo Nordisk A/S drug Ozempic from $1,300 to $150 shakes GLP-1 gold rush, with potential imp...

eli-lilly-releases-phase-3-monarche-trial-results-showing-that-two-years-of-verzenio-plus-endocrine-therapy-reduced-the-risk-of-death-by-158-compared-to-endocrine-therapy-alone-and-delivered-sustained-improvements-in-invasive-disease-free-and-distant-relapse-free-survival-for-patients-with-hr-her2--high-risk-early-breast-cancer
Eli Lilly Releases Phase 3 monarchE Trial ...
10/17/2025 12:05:45

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvan...

eli-lilly-novo-nordisk-hims--hers-health-shares-move-lower-after-trump-calls-out-fat-loss-drugs
Eli Lilly, Novo Nordisk, Hims & Hers Healt...
10/16/2025 21:24:18

Shares of Eli Lilly and Novo Nordisk move lower in Thursday's after-hours session after President Trump indicated weight-lo...

Core News & Articles
President Trump Says I Think The Fat-Loss...
10/16/2025 20:33:25

https://www.youtube.com/watch?v=xagrobF4q1k 

guggenheim-reiterates-buy-on-eli-lilly-maintains-948-price-target
Guggenheim Reiterates Buy on Eli Lilly, Ma...
10/16/2025 12:57:43

Guggenheim analyst Seamus Fernandez reiterates Eli Lilly (NYSE:LLY) with a Buy and maintains $948 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION